AnaptysBio Inc
Avatud
SektorTervishoid
55.06 -1.22
Ülevaade
Aktsiahinna muutus
24h
Min
54.29
Max
56.19
Sissetulek | -102M -53M |
|---|---|
Müük | -83M 26M |
Aktsiakasum | -1.34 |
Kasumimarginaal | -206.934 |
Töötajad | 104 |
EBITDA | -99M -31M |
Järgmine tulemuste avaldamine | 15. sept 2026 |
|---|
Turukapital | -295M 1.7B |
|---|---|
Eelmine avamishind | 56.28 |
Eelmine sulgemishind | 55.06 |
Uudiste sentiment
By Acuity
36%
64%
100 / 339 Pingereas Healthcare
AnaptysBio Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
AnaptysBio Inc Prognoos
Sentiment
By Acuity
100 / 339 Pingereas Tervishoid
Uudiste sentiment
Languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
